...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Prescrire international >Palbociclib (ibrance0) and inoperable or metastatic breast cancer Unfavourable harm-benefit balance
【24h】

Palbociclib (ibrance0) and inoperable or metastatic breast cancer Unfavourable harm-benefit balance

机译：Palbociclib（Ibrance0）和无法操作或转移性乳腺癌不利伤害余额

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In patients with advanced or metastatic breast cancer, whose tumour is hormone receptor-positive but does not overexpress the protein HER2, hormonal therapy is often a first choice, using either an oestrogen antagonist such as tamoxifen or an aromatase inhibitor such as letrozole. Palbociclib (Ibrance0, Pfizer) is an antineo-plastic that inhibits protein kinases involved in cell division. It has been authorised in combination with an aromatase inhibitor or the oestrogen antagonist fulvestrant. Palbociclib's evaluation focuses on two double-blind randomised placebo-controlled trials: in one it was added to letrozole in 666 post-menopausal patients not previously treated for this cancer; in the other it was added to fulves-trant in 521 patients in whom hormonal therapy had failed. In both trials, a significant increase in the time to cancer progression (based on radiological assessment) or death was reported in the palbociclib groups. But the preliminary results available in late 2017 do not show that the addition of palbociclib prolongs survival. In these two trials, adding palbociclib increased the incidence of serious adverse effects. These effects result from palbociclib's cytotoxic-like action (haematological disorders, gastrointestinal adverse effects, alopecia), as well as pulmonary and possibly hepatic toxicity. 0 Palbociclib is prone to pharmacokinetic interactions via the cytochrome P450 isoenzyme CYP 3A4 and some transport proteins including P-glycoprotein.
机译：在患有先进或转移性乳腺癌的患者中，其肿瘤是激素受体阳性但不过度表达蛋白质HER2，荷尔蒙治疗通常是第一选择，使用雌激素拮抗剂如Tamoxifen或芳香酶抑制剂如Letrozole。 Palbociclib（Ibrance0，Pfizer）是一种抗肿瘤塑料，抑制涉及细胞分裂的蛋白激酶。它已与芳香酶抑制剂或雌激素拮抗剂氟斯特朗授权。 Palbociclib的评价侧重于两种双盲随机安慰剂对照试验：在未治疗此癌症之前未治疗的666名未经治疗的666名未治疗的前列腺患者中添加到Letrozole中;另一方面，在荷尔蒙治疗失败的521名患者中被添加到富伤训练。在两项试验中，在帕尔伯科基群组中报道了癌症进展（基于放射性评估）或死亡的时间大幅增加。但2017年底可获得的初步结果并不显示添加帕尔巴克测妇延长生存。在这两项试验中，添加Palbociclib增加了严重不良反应的发生率。这些效果由Palbociclib的细胞毒性样作用（血液学疾病，胃肠不良反应，Alopecia）以及肺部和可能肝脏毒性产生。 0 Palbociclib通过细胞色素P450同工酶CYP 3A4和一些包含p-糖蛋白的转运蛋白质容易发生药代动力学相互作用。

著录项

  • 来源
    《Prescrire international》 |2018年第190期|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号